[go: up one dir, main page]

AR056992A1 - Derivados de pirimidina - Google Patents

Derivados de pirimidina

Info

Publication number
AR056992A1
AR056992A1 ARP060101670A ARP060101670A AR056992A1 AR 056992 A1 AR056992 A1 AR 056992A1 AR P060101670 A ARP060101670 A AR P060101670A AR P060101670 A ARP060101670 A AR P060101670A AR 056992 A1 AR056992 A1 AR 056992A1
Authority
AR
Argentina
Prior art keywords
alkyl
aryl
heterocyclic ring
group
cycloalkyl
Prior art date
Application number
ARP060101670A
Other languages
English (en)
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of AR056992A1 publication Critical patent/AR056992A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Derivados 4-aminocarbonil-pirimidina y su uso como antagonistas del receptor P2Y12 en el tratamiento y/o la prevencion y/o el tratamiento de enfermedades o condiciones vasculares periféricas, viceral-, hepático-, y renal-vasculares, cardiovasculares, y cerebrovasculares asociadas con la agregacion de plaquetas, incluyendo trombosis, en humanos y otros mamíferos. Reivindicacion 1: Un compuesto seleccionado desde el grupo que consiste en los compuestos de formula (1) en la cual: R1 representa fenilo opcionalmente sustituido 1 a 3 veces por substituyentes cada uno independientemente seleccionado desde el grupo que consiste en halogeno, metilo, metoxilo, trifluorometilo y trifluorometoxilo; W representa un enlace, y R2 representa alquilo, haloalquilo, ciano, hidroxialquilo, hidroxialquilo substituido en su cadena alquílica con un grupo fenilo no substituido, alcoxialquilo, heterociclilo, heterociclilalquilo, cicloalquilo, cicloalquilalquilo, arilo, heteroarilo, o uno de los radicales 2 a 5 en los cuales m es 0 y n es 2 o 3, o m es 1 y n es 2; p es 0 y q es 2 o 3, o p es 1 y q es 2, o también p es 2 o 3 y q es 0; Q es -CO- o -CH(ORa)-, siendo Ra H o alquilo, y Q' es -CO-; o W representa -CH2- y R2 representa - NR7R8, -SR9 o -SO2R10; W representa -O- o -S- y R2 representa alquilo, carboxialquilo, alcoxicarbonilalquilo, hidroxialquilo, alcoxialquilo, heterociclilalquilo, cicloalquilo, cicloalquilalquilo, arilo, aralquilo, heteroarilo o heteroarilalquilo; W representa -NR3- y R2 representa H, alquilo, dialquilaminoalquilo, alcoxicarbonilalquilo, carboxialquilo, carboxialquilo substituido en su seccion alquilo con un grupo fenilo, hidroxialquilo, alcoxialquilo, heterociclilo, heterociclilalquilo, cicloalquilo, cicloalquilalquilo, arilo, 2-fenilciclopropilo, aralquilo, difenilalquilo, heteroarilalquilo en donde el heteroarilo es un heteroarilo monocíclico, -COR11 o -SO2R12; W representa -CH=CH- y R2 representa alquilo, hidroxialquilo, alcoxialquilo, alcoxicarbonilo, fenilo o -CO-NR13R14; o W representa -C:::C- y R2 representa H, alquilo, hidroxialquilo o alcoxialquilo; o W representa -CO- y R2 representa alquilo; R3 representa H o alquilo; R7 representa alquilo o arilalquilo; R8 representa alquilo; o R7 y R8 forman, en conjunto con el N que los porta, un anillo heterocíclico de 4 a 7 miembros en el cual los miembros que se necesitan para completar dicho anillo heterocíclico se seleccionan de manera independiente de entre - CH2-, -CH(CH3)-, -CHRy-, -O-, -S-, -CO- y -NRz-, entendiéndose sin embargo que dicho anillo heterocíclico no contiene más que un miembro seleccionado desde el grupo que consiste en -CHRy-, -O-, -S-, -CO- y -NRz-, representando Ry hidroxilo, hidroximetilo, alcoximetilo, alcoxicarbonilo o alcoxilo y representando Rz H, alquilo o alcoxicarbonilo; R9 representa cicloalquilo o arilo; R10 representa alquilo, cicloalquilo o arilo; R11 alquilo, alcoxialquilo, cicloalquilo, cicloalquilalquilo, arilo, heteroarilo monocíclico o aralquilo; R12 representa alquilo o arilo; R13 representa alquilo; R14 representa alquilo; o W representa -NR3- y R2 y R3 forman, en conjunto con el N que los porta, un anillo heterocíclico de 4 a 7 miembros en el cual los miembros que se necesitan para completar dicho anillo heterocíclico se seleccionan de manera independiente de entre -CH2-, -CHRx-, -O-, -S-, -CO- y -NR4- y entendiéndose que dicho anillo heterocíclico no contiene más que un miembro seleccionado desde el grupo que consiste en -CHRx-, -O-, -S-, -CO- y -NR4-, representando Rx hidroxilo, hidroximetilo, alcoximetilo o alcoxilo y R4 representando H o alquilo; o también W representa -NR3- y R2 y R3 forman, en conjunto con el N que los porta, ya sea un anillo imidazolilo, pirazolilo, 1,2,3-triazolilo o 1,2,4-triazolilo, anillo que puede estar substituido con un grupo alquilo, o un anillo 4-oxo-4H-piridin-1-ilo, 4,5-dihidro-pirazol-1-ilo, 2-metil-4,5-dihidro-imidazol-1-ilo o 3- metil-5-oxo-2,5-dihidro-pirazol-1-ilo; cada uno de R5a y R5b representa, de manera independiente, H o metilo; X representa -CO- y R6 representa alquilo, cicloalquilo, alcoxilo, alquiniloxilo, ariloxilo, aralcoxilo, arilo, heteroarilo monocíclico, aralquilo o NR15R16, o X representa -SO2- y R6 representa alquilo; R15 representa alquilo; R16 representa H o alquilo; o R15 y R16 forman, en conjunto con el N que los porta, un anillo heterocíclico de 4 a 7 miembros, en el cual los miembros que se necesitan para completar dicho anillo heterocíclico se seleccionan de manera independiente de entre -CH2-, -O-, -S- y -NRw-, representando Rw H o alquilo, entendiéndose que dicho anillo heterocíclico no contiene más que un miembro del grupo que consiste en -O-, -S- y -NRw-; e Y representa un enlace y Z representa H o arilo substituido por carboxialcoxilo; o Y representa alquileno, alcoxialquileno, fenilalquileno, alcoxifenileno o alcoxifenilalquileno y Z representa H, -OH, -NH2, -COOH, tetrazolilo, -CO-NH2, -COOR17, -NH-CO-R17, -NH-COOR17 o -NH-SO2-R17, representando R17 alquilo; y un enantiomero opticamente puro, una mezcla de enantiomeros, un racemato, un diastereoisomero opticamente puro, una mezcla de diastereoisomeros, un racemato diastereoisomérico, una mezcla de racematos diastereoisoméricos, una meso forma, una sal, un complejo disuelto, o una forma morfologica de los mismos.
ARP060101670A 2005-04-28 2006-04-26 Derivados de pirimidina AR056992A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2005004578 2005-04-28
IB2005053711 2005-11-10

Publications (1)

Publication Number Publication Date
AR056992A1 true AR056992A1 (es) 2007-11-07

Family

ID=37075078

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060101670A AR056992A1 (es) 2005-04-28 2006-04-26 Derivados de pirimidina

Country Status (18)

Country Link
US (1) US8048881B2 (es)
EP (1) EP1893634B1 (es)
JP (1) JP4955658B2 (es)
KR (1) KR101310016B1 (es)
CN (1) CN101166756A (es)
AR (1) AR056992A1 (es)
AT (1) ATE538130T1 (es)
AU (1) AU2006241260A1 (es)
BR (1) BRPI0608089A2 (es)
CA (1) CA2604967C (es)
ES (1) ES2377337T3 (es)
IL (1) IL186939A0 (es)
MX (1) MX2007013436A (es)
NO (1) NO20076094L (es)
NZ (1) NZ563584A (es)
RU (1) RU2410393C2 (es)
TW (1) TW200640877A (es)
WO (1) WO2006114774A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009534310A (ja) * 2006-03-29 2009-09-24 武田薬品工業株式会社 レニン阻害剤
CL2007002920A1 (es) * 2006-10-13 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
AR063518A1 (es) * 2006-10-25 2009-01-28 Actelion Pharmaceuticals Ltd Derivados 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y su uso para tratar y/o prevenir enfermedades vasculares perifericas viscerales, hepaticas y renales, enfermedades cardiovasculares y enfermedades cerebrovasculares asociados con la agregacion de plaquetas, incluyendo trombosis
JP5309131B2 (ja) 2007-04-23 2013-10-09 サノフイ Ｐ２ｙ１２アンタゴニストとしてのキノリン−カルボキサミド誘導体
SI2225253T1 (sl) * 2007-11-29 2012-09-28 Actelion Pharmaceuticals Ltd Derivati fosfonske kisline in njihova uporaba kot antagonisti receptorja P2Y12
WO2009080227A2 (en) 2007-12-26 2009-07-02 Sanofi-Aventis Pyrazole-carboxamide derivatives as p2y12 antagonists
JP5504171B2 (ja) * 2007-12-26 2014-05-28 サノフイ Ｐ２ｙ１２アンタゴニストとしてのヘテロサイクリックピラゾール−カルボキサミド
WO2009110985A2 (en) 2008-02-29 2009-09-11 Renovis, Inc. Amide compounds, compositions and uses thereof
AR071653A1 (es) * 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
AR071652A1 (es) * 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2- fenil-piridina substituidos
JP5341069B2 (ja) * 2008-04-22 2013-11-13 第一三共株式会社 ５−ヒドロキシピリミジン−４−カルボキサミド化合物
EP2346825A2 (en) 2008-09-18 2011-07-27 Evotec AG Modulators of p2x3 receptor activity
KR101114503B1 (ko) * 2008-12-04 2012-02-15 지에스건설 주식회사 부유물 수거장치
NZ596213A (en) * 2009-04-08 2013-05-31 Actelion Pharmaceuticals Ltd 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines as adenosine 5'-diphosphate (ADP) receptor antagonists
WO2010122504A1 (en) 2009-04-22 2010-10-28 Actelion Pharmaceuticals Ltd Thiazole derivatives and their use as p2y12 receptor antagonists
EP2471792B1 (en) 2009-08-28 2014-04-09 Daiichi Sankyo Company, Limited 3-(biaryloxy) propionic acid derivative
WO2013033178A1 (en) 2011-08-30 2013-03-07 University Of Utah Research Foundation Methods and compositions for treating nephrogenic diabetes insipidus
WO2013030665A1 (en) 2011-09-02 2013-03-07 Purdue Pharma L.P. Pyrimidines as sodium channel blockers
IL265445B2 (en) 2016-09-22 2024-05-01 Idorsia Pharmaceuticals Ltd crystalline forms
CN110381947A (zh) 2017-03-15 2019-10-25 爱杜西亚药品有限公司 P2y12受体拮抗剂的皮下施用
CN112500354A (zh) * 2020-12-08 2021-03-16 烟台凯博医药科技有限公司 一种4-氯-6-环丙基嘧啶-5-胺的合成方法
WO2025133948A1 (en) 2023-12-21 2025-06-26 Pfizer Inc. Acetyl coa-carboxylase (acc) inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5373586A (en) * 1976-12-09 1978-06-30 Mitsubishi Chem Ind Ltd New penicillin derivatives
US6861424B2 (en) * 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
RU2213744C1 (ru) * 2002-06-27 2003-10-10 Институт органической химии им. Н.Д. Зелинского РАН ПРОИЗВОДНЫЕ АНТРА[2,1-d]ИЗОТИАЗОЛ-3,6,11-ТРИОНА
BR0317222A (pt) 2002-12-11 2005-11-01 Schering Aktiengellschaft Compostos de 2-aminocarbonil-quinolina como antagonistas dos receptores de difosfato de adenisina de plaquetas
CL2007002920A1 (es) 2006-10-13 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
AR063518A1 (es) 2006-10-25 2009-01-28 Actelion Pharmaceuticals Ltd Derivados 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y su uso para tratar y/o prevenir enfermedades vasculares perifericas viscerales, hepaticas y renales, enfermedades cardiovasculares y enfermedades cerebrovasculares asociados con la agregacion de plaquetas, incluyendo trombosis
SI2225253T1 (sl) 2007-11-29 2012-09-28 Actelion Pharmaceuticals Ltd Derivati fosfonske kisline in njihova uporaba kot antagonisti receptorja P2Y12
AR071653A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
AR071652A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2- fenil-piridina substituidos
NZ596213A (en) 2009-04-08 2013-05-31 Actelion Pharmaceuticals Ltd 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines as adenosine 5'-diphosphate (ADP) receptor antagonists
WO2010122504A1 (en) 2009-04-22 2010-10-28 Actelion Pharmaceuticals Ltd Thiazole derivatives and their use as p2y12 receptor antagonists

Also Published As

Publication number Publication date
WO2006114774A3 (en) 2007-02-08
JP4955658B2 (ja) 2012-06-20
CA2604967A1 (en) 2006-11-02
MX2007013436A (es) 2008-01-16
CA2604967C (en) 2014-04-01
BRPI0608089A2 (pt) 2009-11-10
US20080194576A1 (en) 2008-08-14
AU2006241260A1 (en) 2006-11-02
KR101310016B1 (ko) 2013-09-30
KR20080004608A (ko) 2008-01-09
RU2007143880A (ru) 2009-06-10
ATE538130T1 (de) 2012-01-15
IL186939A0 (en) 2008-02-09
EP1893634A2 (en) 2008-03-05
NZ563584A (en) 2011-03-31
RU2410393C2 (ru) 2011-01-27
ES2377337T3 (es) 2012-03-26
NO20076094L (no) 2008-01-25
WO2006114774A2 (en) 2006-11-02
US8048881B2 (en) 2011-11-01
TW200640877A (en) 2006-12-01
CN101166756A (zh) 2008-04-23
EP1893634B1 (en) 2011-12-21
JP2008539224A (ja) 2008-11-13

Similar Documents

Publication Publication Date Title
AR056992A1 (es) Derivados de pirimidina
AR063258A1 (es) Derivados de 2-aminocarbonil-piridina, una composicion farmaceutica que los contiene y su uso en la preparacion de un medicamento para el tratamiento de trastornos vasculares oclusivos.
AR075858A1 (es) Compuestos biciclicos como inhibidores de diacilglicerol aciltransferasa
AR047538A1 (es) Piridazinonas como antagonistas de las integrinas alfa4
AR067996A1 (es) Derivados heterociclicos de ciclopropano,composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento de afecciones asociadas a receptores de histamina h3, tales como enfermedad de alzheimer y esquizofrenia,entre otros.
PE20211871A1 (es) Agonistas de glp-1r y usos de los mismos
CO6160237A2 (es) Pirazinonas y pirazinoles sustituidos y composiciones que los comprenden
AR071652A1 (es) Derivados 2- fenil-piridina substituidos
AR048495A1 (es) Benzoil amino heterociclicos, utiles para el tratamiento de enfermadades intermediadas por glk
PE20041078A1 (es) Derivados heterociclicos inhibidores de la elastasa leucocitica humana (elh)
AR064824A1 (es) Derivados de espirocromanona sustituidos
PE20060374A1 (es) Inhibidores de cinasa heterociclicos fusionados
PE20141827A1 (es) Inhibidores de proteinas quinasas
ES2567311T3 (es) 6-(3-Aza-biciclo[3.1.0]hex-3-il)-2-fenil-pirimidinas como antagonistas del receptor de ADP
ES2452299T3 (es) Compuestos heterocíclicos fungicidas
AR069494A1 (es) Derivados de acidos fosfonicos
PE20050951A1 (es) Compuestos mimeticos de glucocorticoides, metodos de preparacion y composiciones farmaceuticas
PE20060525A1 (es) Compuestos heterociclicos como inhibidores de cetp
AR054365A1 (es) Derivados de heteroaril benzamidas, composiciones farmaceuticas que los contienen, usos en enfermedades mediadas por glucoquinasasy metodo de preparacion de los mismos.
AR047533A1 (es) Proceso para preparar carboxamidas 2-aminotiazol-5-aromaticas como inhibidores de la quinasa
AR064427A1 (es) Derivados heterociclicos de imidazol, composiciones farmaceuticas que los contienen y usos para el tratamiento de trastornos asociados con insuficiencias cognitivas.
AR058984A1 (es) Derivados de ciclohexil piperazinil metanona
NO20073729L (no) Heterocykliske forbindelser som CCR2B-antagonister
CO6220935A2 (es) Derivados de 1,2,4-triazol como moduladores de mglur5
AR070797A1 (es) Derivados de quinoxalinona como estimulantes de la secrecion de insulina, metodos para obtenerlos y su uso en el tratamiento de la diabetes

Legal Events

Date Code Title Description
FA Abandonment or withdrawal